3Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up conforms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide cisplatin combination in advanced ovarian cancer [J]. Int J Gynecol Cancer, 2003, 13(Suppl 2) : 144-148.
1Sterling L, van Lonkhuijzen L, Nyangena J, et al.Protocol develop-ment for ovarian cancer treatment in Kenya: a brief report [J]. Int JGynecol Cancer, 2011 Feb, 21(2): 424-7.
3Alshehri A, Beale P, Yu JQ, et al. Synergism from Combination ofCisplatin and Multicentred Platinums Coded as DH6CI and TH1 inthe Human Ovarian Tumour Models CJ) ? Med Chem, 2011 Nov 1, 7(6):593-8.
5Steven D Hey, Tarun Sarkar, Andrew W, et al.Docetaxel as adjuvantand neoadjuvant treatment for patients with breast cancer[J]. ExpertOpinion on Pharmacotherapy, 2004, 5( 10) ; 2147-2148.
7Hoegh A,Lindholt JS,Basic science review.Vascular dis-tensibility as a predictive tool in the management of small asymptomatic abdominal aortic aneurysms[J].Vasc Endovascular Surg,2009,43(4):333-338.
8Shingu Y,Shiiya N,Ooka T,et al.Augmentation inde X is elevated in aortic aneurysm and dissection[J].Ann Thorac Surg,2009,87(5):1373-1377.
9Várady E,Feher E,Levai A,et al.Estimation of vessel age and early diagnose of atherosclerosis in progeria syndrome by using echo-tracking[J].Clin Hemorheol Microcirc,2010,44(4):297-301.
10Guerin O,Soto ME,Brocker P,et al.Nutritional status assessment during Alzheimer's disease[J].J Nutr Health Aging,2012,9(2):81-84.
